Name: Scott A. Rivkees, M.D.

Current titles:
Professor of Pediatrics
University of Florida Department of Pediatrics

Education:

1974-1978	B.S. Biochemistry, Cook College, Rutgers University, New Brunswick, NJ
1978-1982	M.D. New Jersey Medical School, U.M.D.N.J., Newark, NJ
1986-1989	Postdoctoral Fellow in Neuroscience, Harvard Medical School, Massachusetts General Hospital, Boston, MA

Career:

1982-1985	Resident in Pediatrics, Massachusetts General Hospital
1982-1985	Clinical Fellow in Pediatrics, Harvard Medical School
1985-1986	Clinical Fellow in Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School
1986-1989	Research Fellow, Massachusetts General Hospital
1988-1990	Instructor in Pediatrics, Harvard Medical School, Assistant in Pediatrics, Massachusetts General Hospital
1990-1992	Assistant Professor of Pediatrics, Harvard Medical School
1992-1996	Associate Professor of Pediatrics, Indiana University
1996-2000	Associate Professor of Pediatrics, Yale University
2001-2004	Associate Professor of Pediatrics (with tenure), Yale University
2002-2011	Director Yale Child Health Research Center
2004-2011	Professor of Pediatrics (with tenure), Yale University
2004-2011	Chief, Section of Developmental Endocrinology and Biology
2004-2011	Associate Chair of Yale Pediatrics for Research
2012-	Professor of Pediatrics, University of Florida
2012-6/2019	Chair of Pediatrics, University of Florida
2012-6/2019	Physician in Chief, Shands Hospital for Children
2013-6/2019	Chairman of Pediatrics, Arnold Palmer Hospital, Orlando Health
2013-6/2019	Shands Teaching Hospitals and Clinics, Board of Directors
2017-6/2019	UF Chairman of Pediatrics, Studer Family Children's Hospital, Pensacola
2019-9/2021	State Surgeon General and Secretary of Health of Florida

Board Certification:

1982	National Board of Medical Examination Certification
1986	Certified by the American Board of Pediatrics in Pediatrics
1989	Certified by American Board of Pediatrics in Pediatric Endocrinology
1999	Re-certified by American Board of Pediatrics in Pediatric Endocrinology
2004	Re-certified by American Board of Pediatrics in Pediatric Endocrinology
2014	Re-certified by American Board of Pediatrics in Pediatric Endocrinology

Professional Honors or Recognition:

1978	Selman Waksman Award
1981	Alpha Omega Alpha
1982	Mosby Pediatric Award
1987	Pediatric Career Scientist Training Program Award

1989 Lawson Wilkins Pediatric Endocrine Society/Genentech Clinical Scholar Award
1994 Named "One of America's Best Doctors"
1995 National Institutes of Mental Health Review Panel, Ad hoc member
1995 Society of Pediatric Research
1996 Molecular, Cellular and Developmental Neurobiology National Institutes of Health Review Panel, Permanent member
1998 Serono Visiting Professorship, Univ. of New South Wales, Sydney AU
1998 Visiting Professor, Auckland Univ., Auckland NZ
1998 Integrative and Functional Neuroscience, NIH Review Panel, Permanent member
1998 Chairman, Drugs and Therapeutics Committee, Lawson Wilkins Pediatric Endocrine Society
1998 Keynote Speaker 6TH International Symposium on Adenosine and Adenine Nuclides, Ferrara Italy
1999 Organizing Committee of Purines 2000 International Meeting, Madrid Spain
2000 Donaghue Investigator
2000 Guest Editor, Seminars in Perinatology
2001 Organizing Committee, 7TH International Symposium on Adenosine and Adenine Nuclides, Australia
2001 American Society for Clinical Investigation
2002 Fellow of the American Academy of Pediatrics
2002 Named “One of America's Top Pediatricians"
2002 Molecular, Cellular and Developmental Neurobiology National Institutes of Health Special Emphasis Review Panel
2002 National Heart Lung and Blood Institute, Special Review Panel
2002 US Senate, Expert for Children and Families Subcommittee
2003 Advisory Board CARES
2004 Scientific Advisory Board, Hood Medical Research Foundation
2005 Advisory Board, Annenberg Center, Sleep Disorders in Infancy & Childhood
2005 Rutgers University, George H. Cook Distinguished Alumnus Award
2005 MA Honorary Degree, Yale University
2006 Editor-in-Chief, Journal Pediatric Endocrinology and Metabolism
2006 Chair, Hood Scientific Advisory Board
2006 Connecticut Academy of Science and Engineering (CASE)
2007 Interurban Clinical Club
2008 University of Medicine and Dentistry of New Jersey, Distinguished Alumnus Award
2008 Editor-in-Chief, International Journal of Pediatric Endocrinology
2009 Visiting Professor, Special Symposium, Great Ormond Street Hospital, London
2009 MedScape #1 Endocrine News Story and Alert of 2009
2010 Endocrine Today, Top Ten Endocrine Story of 2010
2010 Special Recognition Award, Lawson Wilkins Pediatric Endocrine Society
2010 Asia Pacific Paediatric Endocrine Society (APPES), Keynote Speaker Award, Xian China
2010 40th, Jahrestagung der Section Schilddruse, Keynote Speaker, Wurzburg GE
2010 48th Nobel Mini-Symposium on Caffeine and Health in Frontiers in Medicine, Stockholm SW
2012 Nemours Eminent Scholar, University of Florida
2012 Fellow of the American Academy for the Advancement of Science
2015 CARES Foundation, Physician of the Year, Pioneer Award
2018 Paul A. Starr Award, American Thyroid Association
2018 Florida Chapter, American Academy of Pediatrics, Special Service Award
2018 Florida Chapter, American Academy of Pediatrics, Treasurer
2019 Association of Medical School Pediatric Department Chairs, Board Member

Professional Service:

1994-1996 Endocrinology Liaison, Indiana St. Dept. Of Health

1995-1996	Director, St. of Indiana, Congenital Hypothyroidism Follow-up Program
1997–2001	Editorial Board, J Clinical Endocrinology and Metabolism
1997-2001	Deputy Section Editor, NeuroReport
1995-1998	Drugs and Therapeutics Committee, Lawson Wilkins Pediatric Endocrine Society
1997-1998	Molecular, Cellular and Developmental Neurobiology National Institutes of Health Review Panel
1998-2001	Integrative and Functional Neuroscience, NIH Review Panel
1998	Endocrinology Liaison, State of Connecticut Department of Pubic Health, Genetics Advisory Panel
1998-1999	Chair, Drugs and Therapeutics Committee, Lawson Wilkins Pediatric Endocrine Society
2000-2005	Town of Orange, Board of Health
2005	Town of Orange, Community Services Committee
2002-2003	Molecular, Cellular and Developmental Neurobiology National Institutes of Health Special Emphasis Review Panel
2002-2004	National Heart Lung and Blood Institute, Special Review Panel
2002	US Senate, Expert for Children and Families Subcommittee
2002-	Director, Yale Child Health Research Center
2003-	Editorial Board, J Clinical Endocrinology and Metabolism
2003	Editorial Board, Journal of Pediatric Endocrinology and Metabolism
2004-	Associate Chair of Pediatrics for Research
2004	Yale School of Medicine Strategic Planning Committee for Basic Research
2005-	Kabi International Growth Study, International Advisory Board
2005-	Director, Yale Pediatric Thyroid Center
2006-	Yale School of Medicine Promotions Committee
2006	NIH Rare Diseases Clinical Research Network Review Committee
2007-	Chair, NIH NICHD Rare Diseases Clinical Research Network Review Committee
2006-	American Thyroid Association
2006-	Editor-in-Chief, Journal of Pediatric Endocrinology and Metabolism
2007-	American Thyroid Association Hyperthyroidism Guidelines Taskforce
2007-	Chair, Public Policy Committee, Lawson Wilkins Pediatric Endocrine Society
2008-	NIH CTSA, Rare Disease Committee
2008-	Editor-in-Chief, International Journal of Pediatric Endocrinology
2008	NICHD Best Pharmaceutical for Children Act Conference, Co-Chair
2008-	NIH NICHDA Review Committee
2009	Public Policy Committee, American Thyroid Association
2009-	NIH NICHDA Review Committee, Chair
2010-	Chair, CASE Public Health Board
2011-	Chair, CASE Biotechnology Board
2012	External Review Panel, NICHD
2012-	Board Member, Florida Chapter of the American Academy of Pediatrics
2014-	Board Member, Shands Hospital
2014-	Public Policy Committee, American Academy of Pediatrics
2014-	Chair, Public Policy Committee, Association of Medical School Pediatric Department Chairs
2014-2016	Chairman of the Board, Greater Orlando Children’s Miracle Network
2015-2019	NICHD, Board of Scientific Counselors, Chair
2019-2023	Board of Directors, American Thyroid Association

Patents

2005 Identification of sex chromosome aneuploidies, mosaicism and abnormalities by single nucleotide polymorphism genotyping. US # 20100196879. Issued 11/2010
2012 Molecular diagnosis of Fragile X syndrome associated with FMR1 gene
2015 Recombinant adeno-associated virus vectors to target medullary thyroid carcinoma. Pending.
2018 Discovery of a novel oligodendrocyte and myelination stimulator. Discovery of a novel oligodendrocyte and myelination stimulator Discovery of a novel oligodendrocyte and myelination stimulator. Pending

Bibliography:

1. Original Peer Reviewed Articles:

1. **Rivkees SA**, Hall DA, Boepple PA, Crawford JD. The reliability of clinical measures of testicular volume. Journal of Pediatrics 110: 914-917, 1987.
2. **Rivkees SA**, Crawford JD. Hypoglycemia pathogenesis in children with dumping syndrome. Pediatrics 80: 937-942, 1987.
3. **Rivkees SA**, Fine BP. The reliability of calculated bicarbonate in clinical practice. Clinical Pediatrics 27: 240-242, 1988.
4. **Rivkees SA**, Crawford JD. The relationship of gonadal activity and chemotherapy included damage. Journal of the American Medical Association 259: 2123-2125, 1988.
5. **Rivkees SA** Bode HH, Crawford JD. Long term growth in juvenile acquired hypothyroidism: failure to achieve normal adult height. New England Journal of Medicine 318: 599-602, 1988.
6. **Rivkees SA**, Hall DA, Weaver DR, Reppert SM. Djungarian hamsters exhibit reproductive responses to changes in daylength at extreme photoperiods. Endocrinology 122: 2634-2638, 1988.
7. Reppert SM, Weaver DR, **Rivkees SA**, Stopa EG. Putative melatonin receptors in a human clock. Science 242: 78-81, 1988.
8. **Rivkees SA**, Fox CA, Jacobson CD, Reppert SM. Anatomic and functional development of the suprachiasmatic nuclei in the gray short-tailed opossum. Journal of Neuroscience 8: 4269-4276, 1988.
9. **Rivkees SA**, Chaar MR, Hanley DF, Maxwell M, Reppert SM, Uhl GR. Localization and regulation of vasopressin mRNA in human neurons. Synapse 3: 246-254, 1989.
10. Weaver DR, **Rivkees SA**, Reppert SM. Localization and characterization of melatonin receptors in rodent brain by in vitro autoradiography. Journal of Neuroscience 9: 2581-2590, 1989.
11. El-Hajj-Fuleihan G, Chen CJ, **Rivkees SA**, Marynick SP, Stock J, Pallatta JA, Brown EM. Calcium-dependent release of N-terminal fragments and intact immunoreactive parathyroid hormone by human pathological parathyroid tissue in vitro. Journal of Clinical Endocrinology and Metabolism 69: 860-867, 1989.
12. **Rivkees SA**, Carlson LL, Reppert SM. G protein regulation of membrane-bound and solubilized melatonin receptors in lizard brain. Proceedings of the National Academy of Sciences USA 86: 3882-3886, 1989.
13. **Rivkees SA**, Cassone VM, Weaver DR, Reppert SM. Melatonin receptors in avian brain: characterization and localization. Endocrinology 125: 363-368, 1989.
14. **Rivkees SA**, Reppert SM. Development of entrainment of circadian phase in the developing gray short tailed opossum: mother vs. environment. American Journal of Physiology 259: E384-388, 1990.
15. **Rivkees SA**, Conron RW, Reppert SM. Solubilization and purification of melatonin receptors from lizard brain. Endocrinology 127: 1206-1214, 1990.
16. Reppert SM, Weaver DR, **Rivkees SA**, Stehle JH. Molecular cloning and characterization of the rat A1-adenosine receptor. Molecular Endocrinology 5: 1037-1048, 1991.

17. **Rivkees SA**, Reppert SM. Appearance of melatonin receptors during embryonic life in Siberian hamsters (Phodopus sungoros). Brain Research 568: 345-352, 1991.
18. Stehle JH, **Rivkees SA**, Lee JJ, Weaver DR, Deeds JD, Reppert SM. The CDNA for an A2-like adenosine receptor. Molecular Endocrinology 6: 384-393, 1992.
19. Reppert SM, Weaver DR, Stehle J, **Rivkees SA**, Grabbe S, Granstein R. Molecular cloning of an orphan G protein-coupled receptor: High expression in lymphocytes and proliferative areas of brain. Cellular and Molecular Neuroscience 3: 206-214, 1992.
20. Fink JS, Weaver DR, **Rivkees SA**, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Molecular Brain Research 14: 186-195, 1992.
21. Weaver DR, **Rivkees SA**, Reppert SM. D1-dopamine receptors activate c-fos expression in the fetal biological clock. Proceedings of the National Academy of Sciences USA. 89:9201-9204, 1992.
22. **Rivkees SA**, Reppert SM. RFL9 encodes an adenosine A2b receptor. Molecular Endocrinology 10: 1598-1604, 1992.
23. **Rivkees SA**, El-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of vitamin D-resistant rickets. Journal of Clinical Endocrinology and Metabolism 75: 1514-1518, 1992.
24. **Rivkees SA**, Weaver DR, Reppert SM. Circadian and developmental regulation of Oct-2 gene expression in the suprachiasmatic nuclei. Brain Research. 598: 332-336, 1992.
25. Linden J, Taylor HE, Robeva AS, Tucker AM, Stehle JH, **Rivkees SA**, Fink JS, Reppert SM. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Molecular Pharmacology 44:524-532, 1993.
26. **Rivkees SA**, Danon M, Herrin. The prednisone dose limits growth hormone treatment of steroid-induced growth failure. Journal of Pediatrics 125:322-325, 1994.
27. **Rivkees SA**. Localization and characterization of adenosine receptor expression in testis. Endocrinology 136:2307-2313, 1994.
28. **Rivkees SA**, Kelley MR. Expression of a Multifunctional DNA Repair Enzyme, Apurinic/Apyrimidinic Endonuclease (APE;REF-1) in the suprachiasmatic, supraoptic, and paraventricular nuclei. Brain Research 666-137-142, 1994.
29. **Rivkees SA**, Price SL, Zhou FC. Immunohistochemical detection of A1 Adenosine receptors in rat brain with emphasis on cellular localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Research 677:193-203, 1995.
30. **Rivkees SA**, Lasbury ME, Stiles GS, Vance, G. Characterization of the human A1 adenosine receptor: ligand binding properties, somatic expression, and chromosomal localization. Endocrine 3:623-629, 1995.
31. Monts BS, Lee WH, Breyer PR, Russell LD, **Rivkees SA**, Pescovitz OH, Srivastiva CH. Identification and localization of secretin and secretin receptor mRNAs in rat testis. Endocrine 3:127-135, 1995.
32. **Rivkees SA**. The ontogeny of cardiac and neural A1 adenosine receptor expression in rats. Developmental Brain Research 89:202-213, 1995.
33. **Rivkees SA**, Lasbury ME, Barbhaiya H. Identification of domains of the human A1 adenosine receptor that are important for binding receptor subtype selective ligands using chimeric A1/A2a adenosine receptors. Journal of Biological Chemistry 270:20485-20490, 1995.
34. Swanson TH, Drazba J, **Rivkees SA**. Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation. Journal of Comparative Neurology 363:517-531, 1995.
35. Wilson TM, **Rivkees SA**, Deutsch WA, Kelley MR. Differential expression of the apurinic/apyrimidinic endonuclease (APE/ref-1) multifunctional DNA base excision repair gene during fetal development and in adult brain. Mutation Research 362:237-248, 1996.

36. Barbhaiya H, McClain R, IJzerman A, **Rivkees SA**. Site directed mutagenesis of the human A_1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. Molecular Pharmacology 50:1635-1642, 1996.
37. **Rivkees SA**, Lachowicz. Functional D1 and D5 dopamine receptors are expressed in the suprachiasmatic supraoptic, and paraventricular nuclei of primates. Synapse 26:1-10, 1997.
38. **Rivkees SA**, Hofman PL, Fortman J. Newborn primate infants are entrained by low intensity lighting. Proceedings of the National Academy of Sciences USA. 94:292-297, 1997.
39. Bender M, Drago J, **Rivkees SA**. D1 receptors mediate dopamine action in the fetal suprachiasmatic nuclei: Studies of mice with targeted deletion of D1 dopamine receptors. Molecular Brain Research. 49: 271-277, 1997.
40. Hofman PL, Yoder MC, **Rivkees SA**. A1 adenosine receptors potently regulate murine embryonic cardiac function. American Journal of Physiology. 272: R1374-1380, 1997.
41. Middlekauff, HR, **Rivkees SA**, Raybould H.E. Bitticaca, M., Goldhaber, J.I., Weiss, J.N. Localization and functional affects of adenosine A1 receptor on cardiac vagal afferents in adult rats. American Journal of Physiology 274: H441-H447, 1998.
42. Swanson TS, **Rivkees SA**. Evidence for physiologically active axonal adenosine receptors in the rat corpus callosum. Brain Research 784:188-198, 1998.
43. **Rivkees SA**, Barbhaiya HB, IJzerman, AP. Identification of the adenine binding site of the Human A1 Adenosine Receptor. Journal of Biological Chemistry 274: 3617-3621, 1999.
44. Rice AR, **Rivkees SA**. Etridonate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. Pediatrics 134:349-351, 1999.
45. Hao H, **Rivkees SA**. The biological clock of very premature primate infants is responsive to light. Proceedings of the National Academy of Sciences USA. 96: 2426-2429, 1999.
46. **Rivkees SA**, Chen MC, Kulkarni J, Browne J, Zhao Z. Characterization of the murine A1 adenosine receptor promoter: potent regulation by GATA-4 and NKX 2.5 Journal of Biological Chemistry 274:14204-14209, 1999.
47. Bode HH, **Rivkees SA**, Cowley DM, Pardy K, Johnson S. Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples. Journal of Pediatrics. 1999 Feb;134(2):185-9.
48. Rice AR, Fain J, **Rivkees SA**. A1 adenosine receptors potently regulate leptin secretion. Endocrinology 141:1442-5, 2000.
49. Zhao Z, **Rivkees SA**. Programmed cell death in the developing heart: Regulation by BMP4 and FGF2. Developmental Dynamics 217:388-400, 2000.
50. **Rivkees SA**, Thevananther S, Hao H. Are A3 Adenosine Receptors Expressed in the Brain? Neuroreport 11:1025-1030, 2000.
51. Pogacar PR, Mahnke S, **Rivkees SA**. Management of central diabetes insipidus in infancy with low renal solute load formula and chlorothiazide. Current Opinions in Pediatrics 12:405-411, 2000.
52. Eugster E, Quigley C, Pescovitz OH, **Rivkees SA**. Development of a congenital hypothyroidism follow-up program. Endocrinologist 10:185-195, 2000
53. **Rivkees SA**, Crawford JD. Dexamethasone treatment of congenital adrenal hyperplasia: the ability to achieve normal growth Pediatrics. 106:767-73, 2000.
54. Zhao Z, **Rivkees SA**. Tissue-specific expression of murine GTPases RalA and RalB during embryogenesis and regulation by epithelial-mesenchymal interactions. Mechanisms of Development 97:201-204, 2000.
55. Hao H, **Rivkees SA**. Melatonin does not induce phase shifts in primates. Journal of Clinical Endocrinology and Metabolism. 85:3618-3622, 2000.
56. Fain JN, Leffler CW, Bahouth SW, Rice AM, **Rivkees SA**. Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue. Prostoglandins and Lipid Mediators 62:343-350, 2000.

57. Porter GA, **Rivkees SA**. The ontogeny of humoral regulation of embryonic cardiac function. Am Journal of Physiology 281:R401-R407, 2001.
58. Zhao Z, **Rivkees SA**. Adenosine inhibits cell division in the embryonic heart Developmental Dynamics 221:194-200, 2001.
59. Thevanather S, Rivera A, **Rivkees SA**. Adenosine receptor activation inhibits neurite growth by Rho-Associated-Kinase-mediated mechanisms. NeuroReport 12:3057-3063, 2001.
60. Wei L, Roberts W, Wang L, Yamada M, Zhang S, Zhao Z, **Rivkees SA**, Schwartz RJ, Imanaka-Yoshida. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 128:2953-2962, 2001.
61. **Rivkees SA**. Arrythmicity in septo-optic dysplasia and establishment of sleep-wake cyclicity with melatonin. Journal of Pediatrics139:463-465, 2001.
62. Yan H, **Rivkees SA**. Hepatocyte growth factor stimulates the proliferation and migration of oligodendrocyte precursor cells. J Neurosci Res. 2002 69(5):597-606.
63. Turner CP, Yan H, Schwartz M, Othman T, **Rivkees SA**. A1 adenosine receptor activation induces ventriculomegaly and white matter loss. NeuroReport. 2002;13(9):1199-204.
64. Rentschler S, Zander J, Meyers K, France D, Levine R, Porter G, **Rivkees SA**, Morley GE, Fishman GI. Neroregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci U S A. 2002 99(16):10464-9.
65. Porter GA Jr, Makuck RF, **Rivkees SA**. Reduction in intracellular calcium levels inhibits myoblast differentiation. J Biol Chem. 2002 277(32):28942-7.
66. Turner CP, **Rivkees SA**. Reduction in intracellular calcium levels induces injury in developing neurons. Experimental Neurology 2002 178(1):21-32.
67. Zhao Z, **Rivkees SA**. Rho-associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation. Devel Dynamics 2003 226(1):24-32.
68. Lisska MC, **Rivkees SA**. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003 16(5):711-8.
69. **Rivkees SA.** Rest-activity patterns in children with hypopituitarism. Pediatrics 2003 111(6 Pt 1):e720-4.
70. Porter GA Jr, Makuck RF, **Rivkees SA.** Intracellular calcium plays an essential role in cardiac development. Devel Dynamics 2003 227(2):280-90.
71. **Rivkees SA,** Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003 111:745-9.
72. Othman T, Yan H, **Rivkees SA.** Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia. 2003 44(2):166-72.
73. Yan H, Lu D, **Rivkees SA.** Lysophosphatidic acid regulates the proliferation and migration of olfactory ensheathing cells in vitro.Glia. 2003 44(1):26-36.
74. Turner CP, Seli M, Ment L, Stewart W, Blackburn M, Johansson J, Fredholm B, **Rivkees SA.** A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc Natl Acad Sci U S A. 2003 100(20):11718-22
75. Lu D, Yan H, Othman T, Turner CP, Woolf T, **Rivkees SA.** Cytoskeletal protein 4.1G binds to the third intracellular loop of the A1 adenosine receptor and inhibits receptor action. Biochem J. 2004;377(Pt 1):51-9.
76. Turner CP, Blackburn MR, **Rivkees SA.** A1 adenosine receptors mediate hypoglycemia-induced neuronal injury. J Mol Endocrinol. 2004 32(1):129-44.
77. **Rivkees SA,** Mayes L, Jacobs H, Gross I. Rest-activity patterns of premature infants are regulated by cycled lighting. Pediatrics. 2004 Apr;113(4):833-9.
78. Gascard, PD, Parra MK, Zhao Z, Calinisan VR, Nunomura W, **Rivkees SA,** Mohandas, N, Conboy JG. Putative Tumor Suppressor Protein 4.1B is differentially expressed in kidney and brain via alternative promoters and 5' alternative splicing: Implication for diverse roles for 4.1B in kidney and brain physiology. Biochimica et Biophysica Acta 2004 1680(2):71-82.

79. Lu D, Yan, H, Othman T, **Rivkees SA.** 4.1G Is a Binding Partner of the Metabotropic Glutamate Receptor Subtype 1 Alpha. Journal of Neuroscience Research 2004 1;78(1):49
80. Zhao Z, **Rivkees SA.** Rho-associated kinases play a role in endocardial cell differentiation and migration. Dev Biol. 2004 Nov 1;275(1):183-91.
81. Kim M, Yu Z, Fredholm BB. **Rivkees, SA.** Susceptibility of the developing brain to acute hypoglycemia involving A1 adenosine receptor activation Am J Physiol Endocrinol Metab. 2005 289(4):E562-9.
82. Meng H, Hager K, **Rivkees SA**, Gruen JR. Detection of Turner syndrome using high-throughput quantitative genotyping. J Clinic Endo and Metabolism 2005 90(6):3419-22.
83. de Ligt RA, **Rivkees SA,** Lorenzen A, Leurs R, IJzerman AP. . A "locked-on," constitutively active mutant of the adenosine A1 receptor. Eur J Pharmacol. 2005 7;510(1-2):1-8.
84. Yan H, **Rivkees SA.** Hypoglycemia influences oligodendrocyte development and myelin formation NeuroReport 2006 23;17(1):55-9.
85. Wendler CC, **Rivkees SA.** Spingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Developmental Biology 2006 15;291(2):264-77.
86. Back SA, Craig A, Luo AL, Akundi Shankar R, Ribeiro I, **Rivkees, SA**. Protective Effects of Caffeine on Chronic Hypoxia-Induced Perinatal White Matter Injury. Annals Neurology 2006 Dec;60(6):696-705 .
87. Wendler CC, McClaskey C, Ghatpande S, Fredholm B, **Rivkees SA.** A1 Adenosine Receptors Play an Essential Role in Protecting the Embryo against Hypoxia Proc Natl Acad Sci U S A. 2007 5;104(23):9697-702.
88. Muinck ED, Nagy N, Tirziu D, Murakami M, Gurusamy N, Goswami SK, Ghatpande S, **Rivkees SA,** Engelman RM, Simons M, Das DK. Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling. Antioxid Redox Signal. 2007 9(4):437-45.
89. Ghatpande SK, Billington CJ Jr**., Rivkees SA,** Wendler CC. Hypoxia induces cardiac malformations via A1 adenosine receptor activation in chicken embryos.. Birth Defects Res A 2008 Clin Mol Teratol. 2008 Mar;82(3):121-30.
90. Akundi RA, **Rivkees SA.** Hypoxia induces alteration of oligodendrocyte maturation and cell cycle regulation. PLoS ONE. 2009;4(3):e4739. Epub 2009 Mar 9.
91. Wendler CC, Busovsky-McNeal M, Ghatpande S, Kalinowski A, Russell KS, **Rivkees SA.** Embryonic caffeine exposure induces adverse effects in adulthood. 2009 FASEB J. 2009;23(4):1272-8. 28.
92. **Rivkees SA,** Mattison, D, Ending Propylthiouracil (PTU)-induced Liver Failure in Children, New Eng J Medicine 2009 .9;360(15):1574-5.
93. **Rivkees SA**, Stephenson K, Dinauer C. Adverse Events Associated with Methimazole Therapy of Graves' Disease in Children. International Journal of Pediatric Endocrinology 2010;2010:176970. Epub 2010 Mar 7.
94. **Rivkees SA,** Stephenson K, Low-Dose Dexamethasone Therapy from Infancy of Virilizing Congenital Adrenal Hyperplasia. International Journal of Pediatric Endocrinology 2010;2010:569680.
95. **Rivkees SA,** Fink C, Nelson M, Borchert, M. Prevalence and Risk Factors for Disrupted Circadian Rhythmicity in Children with Optic Nerve Hypoplasia. British J Ophthalmology. 2010;94(10):1358-62.
96. Fogal BF Yan H, Yan S, McClasky C, **Rivkees SA**. Diazoxide promotes oligodendrocyte precursor cell proliferation and myelination. PLoS One. 2010 May 28;5(5):e10906.
97. **Rivkees SA**, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in pediatric patients. Journal of Clinical Endocrinology & Metabolism 2010;95(7):3260-7.

98. Wendler CC, Poulsen RR, Ghatpande S, Greene RW, **Rivkees SA**. Identification of the heart as the critical site of adenosine mediated embryo protection. BMC Dev Biol. 2010:28;10:57.
99. **Rivkees SA,** Hager K, Hosono S, Wise A, Li P, Rinder HM, Gruen JR. A Highly sensitive, high-throughput assay for the detection of Turner Syndrome. Journal of Clinical Endocrinology & Metabolism. J Clin Endocrinol Metab. 2011;96(3):699-705.
100. Poulsen Ryan, McClaskey C, **Rivkees SA,** Wendler C. Sphingosine-1-phospate receptor 1 (S1P1R) mediates S1P action during cardiac development. BMC Dev Biol. 2011 Jun 13;11:37.
101. Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees SA, Reiners C, Hänscheid H. I-131 Activities as High as Safely Administrable (AHASA) for the Treatment of Children and Adolescents with Advanced Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2011 96(8):E1268-7.1
102. van Veenendaal NR, **Rivkees** SA. Treatment of pediatric Graves' disease is associated with excessive weight gain. J Clin Endocrinol Metab. 2011 Oct;96(10):3257-63.
103. Buscariollo DL, Breuer GA, Wendler CC, **Rivkees** SA. Caffeine acts via A1 adenosine receptors to disrupt embryonic cardiac function. PLoS One. 2011;6(12):e28296. doi: 10.1371/journal.pone.0028296.
104. Prindaville B, **Rivkees** SA. Incidence of vitiligo in children with Graves' disease and Hashimoto's thyroiditis. Int J Pediatr Endocrinol. 2011 Nov 18;2011(1):18. doi: 10.1186/1687-9856-2011-18.
105. **Rivkees** SA. Ending the late diagnosis of Turner syndrome through a novel high-throughput assay. Pediatr Endocrinol Rev. 2012 2:698-700.
106. Benavides VC, Mallela MK, Booth CJ, Wendler CC, **Rivkees** SA. Propylthiouracil is teratogenic in murine embryos. PLoS One. 2012;7(4):e35213. doi: 10.1371/journal.pone.0035213
107. Hager K, Jennings K, Hosono S, Howell S, Gruen JR, **Rivkees** SA, Tartaglia NR, Rinder HM. Molecular diagnostic testing for Klinefelter syndrome and other male sex chromosome aneuploidies. Int J Pediatr Endocrinol. 2012 Apr 23;2012(1):8. doi: 10.1186/1687-9856-2012-8.
108. Breuer CK, Solomon D, Donovan P, **Rivkees** SA, Udelsman R.Effect of patient Age on surgical outcomes for Graves' disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center.Int J Pediatr Endocrinol. 2013 25;2013(1):1. doi: 10.1186/1687-9856-2013-1.
109. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, **Rivkees** S. Prevalence of Thyrotoxicosis, Anti-Thyroid Medication Use, and Complications among Pregnant Women in the United States. Thyroid. 2013 Jun;23(6):758-65.
110. van Veenendaal NR, Ulmer B, Boskovski MT, Fang X, Khokha MK, Wendler CC, Blum M, **Rivkees** SA.Embryonic exposure to propylthiouracil disrupts left-right patterning in Xenopus embryos. FASEB J. 2013 Feb;27(2):684-91.
111. Wendler CW, Pilson R, Buscariello D, Greenwood V. **Rivkees SA.** Embryonic Caffeine Exposure Acts via A1 Adenosine Receptors to Alter Adult Cardiac Function and DNA Methylation in Mice. PLOS One 2014 27;9(1):e87547. 10.1371/journal.pone.0087547.
112. Cox MM, Wendler CC, Erdelyi I, Beck A, Zeiss C, **Rivkees SA.** Chronic Neonatal Diazoxide Therapy Is Not Associated with Adverse Effects. (in press).
113. Mallela MK, Stroble M, Wendler CC, Booth CJ, **Rivkees SA.** Evaluation of Developmental Toxicity of Propylthiouracil and Methimazole. (in press). Birth Defects Res B Dev Reprod Toxicol. 2014 Jun 30. doi: 10.1002/bdrb.21113
114. Buscariollo DL, Fang X, Greenwood V, Xue H, **Rivkees** SA, Wendler CC. Embryonic caffeine exposure acts via A1 adenosine receptors to alter adult cardiac function and DNA methylation in mice. PLoS One. 2014 Jan 27;9(1):e87547. doi: 10.1371/journal.pone.0087547.

115. Zhu Y, Wendler CC, Shi O, **Rivkees SA.** Diazoxide Promotes Oligodendrocyte Differentiation in Periventricular White Matter Injury. Brain Research 2014; in press).
116. Fang X, Mei W, Barbazuk WB, **Rivkees SA**, Wendler CC. Caffeine Exposure Disrupts Cardiac Gene Expression in Embryonic Cardiomyocytes. Am J Physiol Regul Integr Comp Physiol. 2014 15;307(12):R1471-87.
117. Lee HU, Woo DH, Bukalo O, Pajevic S, Lee PR, Wake H, Basser P, Dutta DJ, Zhu Y, **Rivkees SA**, Psachoulia K, Fields RD. Astrocyte Regulation of Myelin Structure, Node of Ranvier, and Impulse Conduction. (2014; in press).
118. Paradise Black NM, Black EW, **Rivkees SA.** Implementation of a Novel Track-Based Pediatric Residency Training Program. J Pediatrics 2014;165(6):1076-7
119. Cox MM, Wendler CC, Erdelyi I, Beck A, Zeiss C, **Rivkees** SA. Chronic Neonatal Diazoxide Therapy is not Associated with Adverse Effects. J Biol Sci. 2014 Jan 1;14(1):49-56.
120. Mallela MK, Strobl M, Poulsen RP, Wendler CC, Booth CJ, **Rivkees SA.** Evaluation of Developmental Toxicity of Propylthiouracil and Methimazole. Birth Defects Research. Part B, Developmental and Reproductive Toxicology Birth Defects Res B Dev Reprod Toxicol. **2014** Aug;101(4):300-7.
121. Carter CG, Thompson LA, Silverstein JH, Tuli SY, Black NM, **Rivkees SA**. Pediatrics After-Hours (PAH): A Twenty-Year Academic-Community Partnership for Acute Care Delivery. J Pediatrics J Pediatr. 2015 Apr;166(4):788-9.
122. Wendler CC, Fang X, Poulson R, **Rivkees SA**, Wendler CC. Embryonic Caffeine Exposure Results in Transgenerational Cardiac Dysfunction. Nature. Scientific Reports (in final review).
123. Lo JC, **Rivkees** SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW.Gestational Thyrotoxicosis, Antithyroid Drug Use and Neonatal Outcomes Within an Integrated Healthcare Delivery System. **Thyroid.** 2015 Apr 14.
124. Fang X, Robinson J, Wang-Hu J, Jiang L, Freeman DA, **Rivkees** SA, Wendler CC. Cyclic AMP induces hypertrophy and alters DNA methylation in HL-1 cardiomyocytes. Am J Physiol Cell Physiol. 2015 Jul 29:ajpcell.00058.2015. doi: 10.1152/ajpcell.00058.2015.
125. Abi-Raad R, Virk RK, Dinauer CA, Prasad A, Morotti RA, Breuer CK, Sosa JA, Udelsman R, **Rivkees** SA, Prasad ML. C-Cell Neoplasia in Asymptomatic Carriers of RET Mutation in Extracellular Cysteine-Rich and Intracellular Tyrosine Kinase Domain. Hum Pathol. 2015 Aug;46(8):1121-8. doi: 10.1016/j.humpath.2015.04.011. Epub 2015 May 6.
126. Strobl MT, Freeman D, Patel J, Poulsen R, Wendler CC, **Rivkees SA**, Coleman JE. Opposing effects of maternal hypo- and hyperthyroidism on the stability of thalamocortical synapses in the visual cortex of adult offspring. Cereb Cortex. 2016 May 26. pii: bhw096.
127. Giunta N, Philip C, Saliba H**, Rivkees** SA, Nackashi J. The State of Florida, University-based Ped-I-Care Program for Children with Special Health Care Needs. J Pedatrics 2016 Mar;170:5-6.e1. 1
128. Fang X, Poulsen RR, **Rivkees** SA, Wendler CC. In Utero Caffeine Exposure Induces Transgenerational Effects on the Adult Heart. Sci Rep. 2016 Sep 28;6:34106. doi: 10.1038/srep34106.
129. Fang X, **Rivkees** SA, Wendler CC. Knockdown of DNA Methyltransferase 3a Alters Gene Expression and Inhibits Function of Embryonic Cardiomyocytes. FASEB 2016 Sep;30(9):3238-55.
130. Tang L, Fang X, Winesett SP, Cheng CY, Binder HJ, **Rivkees SA**, Cheng SX. Bumetanide increases Cl--dependent short-circuit current in late distal colon: Evidence for the presence of active electrogenic Cl- absorption. PLoS One. 2017 Feb 2;12(2):e0171045. doi: 10.1371/journal.pone.0171045. eCollection 2017.
131. Clement SC, Kremer LCM, Verburg FA, Simmons JH, Goldfarb M, Peeters RP, Alexander EK, Bardi E, Brignardello E, Constine LS, Dinauer CA, Drozd VM, Felicetti F, Frey E, Heinzel A, van den Heuvel-Eibrink MM, Huang SA, Links TP, Lorenz K, Mulder RL, Neggers SJ, Nieveen van Dijkum EJM, Oeffinger KC, van Rijn RR, **Rivkees SA,** Ronckers CM, Schneider

AB, Skinner R, Wasserman JD, Wynn T, Hudson MM, Nathan PC, van Santen HM. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev. 2017 Nov 14;63:28-39. doi: 10.1016/j.ctrv.2017.11.005.

132. Chen JG, Saidi A, **Rivkees** S, Black NP. University- Versus Community-Based Residency Programs: Does the Distinction Matter? J Grad Med Educ. 2017 Aug;9(4):426-429.
133. **Rivkees** SA, Kelly M, Lodish M, Weiner D. The Pediatric Medical Student Research Forum: Fostering Interest in Pediatric Research. J Pediatr. 2017;188:3-4
134. **Rivkees** SA, Denne S. Influences of medications on the developing fetus: toward deciphering the unknowns. Pediatr Res. 2017 Nov;82(5):723-724.
135. **Rivkees** SA. Work Equity and Investment-based Pediatric Departmental Reorganization. J Pediatr. 2017;190:6-7.
136. Chen JG, Saidi A, **Rivkees** S, Black NP. University- Versus Community-Based Residency Programs: Does the Distinction Matter? J Grad Med Educ. 2017;9(4):426-429.
137. Laventhal NT, **Rivkees** SA, Opipari VP. Hope vs. caution: ethical and regulatory considerations for neonatal stem cell therapies. Pediatr Res. 2018 Mar;83(3):557-558.
138. **Rivkees** SA, Opipari V. The missing link in autism spectrum disorder: a specific cause and the practitioner. Pediatr Res. 2018;84(2):151-152
139. Jagsi R, **Rivkees** S, Opipari VP. An unbiased view about bias: Not yet.Pediatr Res. 2019 Jul;86(1):10-11
140. **Rivkees** SA, Opipari V; Pediatric Policy Council. Ensuring the care for our youngest graduates with medically complex conditions. Pediatr Res. 2019 Feb;85(3):253-254.
141. Fleiss B, **Rivkees** SA, Gressens P. Early origins of neuropsychiatric disorders. Pediatr Res. 2019 Jan;85(2):113-114.
142. Levy HC, Hulvey D, Adamson-Small L, Jn-Simon N, Prima V, **Rivkees SA**, Hobbs JA. Improved cell-specificity of adeno-associated viral vectors for medullary thyroid carcinoma using calcitonin gene regulatory elements. PLoS One. **2020**; 15(2): e0228005.
145. Jagsi R, **Rivkees** S, Opipari VP. An unbiased view about bias: Not yet. Pediatr Res. 2019 Jul;86(1):10-11.
146. **Rivkees SA**, Opipari V; Pediatric Policy Council. Ensuring the care for our youngest graduates with medically complex conditions. Pediatr Res. 2019 Feb;85(3):253-254.
147. Matthias J, Spencer EC, Michniewicz M, Bendle TM, Wilson C, Scheppke KA, Blackmore C, Otis A, Rivkees SA. SARS-COV-2 ANTIBODY PREVALENCE AMONG HEALTHCARE WORKERS AND FIRST RESPONDERS, FLORIDA, MAY-JUNE 2020. Fla Public Health Rev. 2021 Feb 25;18(1):1-10.
148. Stack BC Jr, Twining C, Rastatter J, Angelos P, Baloch Z, Diercks G, Faquin W, Kazahaya K, Rivkees S, Sheyn T, Shin JJ, Smith J, Thompson G, Viswanathan P, Wassner A, Brooks J, Randolph GW. Consensus Statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section (AHNS) on Pediatric Benign and Malignant Thyroid Surgery. Endocr Pract. 2021 Mar;27(3):174-184. doi: 10.1016/j.eprac.2020.12.001.
149.. Doyle T, Kendrick K, Troelstrup T, Gumke M, Edwards J, Chapman S, Propper R, Rivkees SA, Blackmore C. COVID-19 in Primary and Secondary School Settings During the First Semester of School Reopening - Florida, August-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441. doi: 10.15585/mmwr.mm7012e2.
150. Stack BC Jr, Twining C, Rastatter J, Angelos P, Baloch Z, Diercks G, Faquin W, Kazahaya K, Rivkees S, Sheyn T, Shin JJ, Smith J, Thompson G, Viswanathan P, Wassner A, Brooks J, Randolph GW. Consensus statement by the American Association of Clinical Endocrinology (AACE) and the American Head and Neck Society Endocrine Surgery Section

(AHNS-ES) on Pediatric Benign and Malignant Thyroid Surgery. Head Neck. 2021 Apr;43(4):1027-1042. doi: 10.1002/hed.26586. Epub 2021 Jan 1.

151. Rivkees SA, Roberson S. The Florida Department of Health STEPS Public Health Approach: The COVID-19 Response Plan and Outcomes Through May 31, 2020. Public Health Rep. 2020 Sep/Oct;135(5):560-564. doi: 10.1177/0033354920946785. Epub 2020 Aug 6.
152. van Santen HM, Alexander EK, Rivkees SA, Frey E, Clement SC, Dierselhuis MP, Lebbink CA, Links TP, Lorenz K, Peeters RP, Reiners C, Vriens MR, Nathan P, Schneider AB, Verburg F. Clinical considerations for the treatment of secondary differentiated thyroid carcinoma in childhood cancer survivors. Eur J Endocrinol. 2020 Sep;183(3):P1-P10. doi: 10.1530/EJE-20-0237.
153. Thompson LA, Mercado RE, Gurka MJ, Rivkees SA. A Centralized Research Hub in a Pediatric Academic Center. J Pediatr. 2020 Mar;218:5-6. doi: 10.1016/j.jpeds.2019.12.001.
154. Stratakis CA, Rivkees SA.Preventing disease in the twenty-first century: "Life is short, the Art long, opportunity fleeting…". Pediatr Res. 2020 Jan;87(2):181-182. doi: 10.1038/s41390-019-0655-6. Epub 2019 Nov 4.
155. Rivkees SA, Roberson S, Blackmore C. Outcomes of COVID-19 Vaccination Efforts in Florida from December 14, 2020 to March 15, 2021 Focusing on Older Individuals, MEDRXIV/2021/254722
156. Gumke M, Dotson N, Blackmore C, Rowlinson MC, Blanton J, Schmedes S, Rivkees SA, Eisenstein L. Cases of SARS-CoV-2 Variant B.1.1.7 in Florida—January 2021–February 2021. (in review).
157. Ursula K Weiss, Jason D Maynard, Katherine McDaniel, Alyssa Cohen, Marie Bailey, and Scott A Rivkees. Comorbidity Risk Factors Contributing to COVID-19 Related Deaths in Florida, March 1, 2020-January 16, 2021. MEDRXIV/2021/255434
158. Fang, X, Poulsen1 R, Zhao L, Wang J, Rivkees SA, Wendler CC. Knockdown of DNA methyltransferase 1 alters DNA methylation and expression patterns of cardiac genes in embryonic cardiomyocytes. FEBS Open Bio (in press).

2. Case reports

1. **Rivkees SA**, Hardin D. Cretinism following weekly dosing of levothyroxine for the treatment of congenital hypothyroidism. Journal of Pediatrics 125:147-149, 1994.
2. Andreoli SP, **Rivkees SA**, Bull M. Hypercalcemia, hypercalciuria, medullary nephrocalcinosis, and renal insufficiency in a toddler with Down syndrome. Pediatric Nephrology. 9:673, 1995.
3. Ahrens WA, Barron-Rodriguez LP, McKee M, **Rivkees S**A, Reyes-Mugica M. Clear Cell Adenocarcinoma of the Cervix in a Child without In Utero Exposure to Diethylstilbestrol: A Case Report and Review of the Literature. Pediatr Dev Pathol. 2005;8(6):690-5.
4. **Rivkees SA.** Thyrotrope Hyperplasia. J Pediatr Endocrinol Metab. 2006 19(12):1395.
5. Torjusen E, Calderon J, **Rivkees SA.** Anaphylactic Reaction to Recombinant Insulin-like Growth Factor-1. 2008 ;21(4):381-4.
6. Benavides V**, Rivkees SA**. Acute myopathy following radioactive iodine therapy for Graves' disease. 2010. Internat J Pediatr Endocrinol. 2010;2010. pii: 717303
7. Patel A, **Rivkees SA.** Prenatal virilization associated with paternal topic androgen use. 2010. Internat J Pediatr Endocrinol. 2010;2010:867471.
8. Canadas KT, **Rivkees** SA, Udelsman R, Breuer CK. Resistance to thyroid hormone associated with a novel mutation of the thyroid β receptor gene in a four-year-old female. Int J Pediatr Endocrinol. 2011;2011(1):3. doi: 10.1186/1687-9856-2011-3.

3. Reviews, Chapters:

1. Reppert SM, Weaver DR, **Rivkees SA**: Maternal communication of circadian phase to the developing mammal. Psychoneuroendocrinology 13: 63-78, 1988.
2. Reppert SM, **Rivkees SA**: Development of human circadian rhythms: Implications for health and disease. IN: Development of circadian rhythmicity and photoperiodism in mammals. Ed. SM Reppert. Perinatology Press, Ithaca, NY, 1989. pp. 245-259.
3. Reppert SM, **Rivkees SA**, Weaver DR: Prenatal function and entrainment of a circadian clock. IN: Development of circadian rhythmicity and photoperiodism in mammals. Ed. SM Reppert. Perinatology Press, Ithaca, NY, 1989. pp. 1-24
4. Weaver DR, **Rivkees SA** Carlson LL, Reppert SM. Localization of melatonin receptors in mammalian brain. IN: Suprachiasmatic Nucleus: The Mind's Clock. Eds. DC Klein, RY Moore, SM Reppert, Oxford Univ. Press, NY, 1991. pp. 289-308.
5. **Rivkees SA**, Reppert SM. Suprachiasmatic nuclei development in an opossum. IN: Suprachiasmatic Nucleus: The Mind's Clock. Eds. DC Klein, RY Moore, SM Reppert, Oxford Univ. Press, NY, 1991. pp. 419-428.
6. **Rivkees SA**. Hyperparathyroidism in Children. IN: Pediatric Endocrinology. Ed. F. Lifschifts. Marcel Dekker, Inc., New York. pp. 497-506.
7. **Rivkees SA**. The role of adenosine in the developing fetus. IN: Purinergic Approaches in Experimental Therapeutics. Ed. K.A. Jacobson. John Wiley & Sons. New York. 1997. Pp. 527-541.
8. **Rivkees SA**. Circadian Rhythmicity in Childhood. Pediatric Clinics of North America. 44:467-487, 1997.
9. Swanson TH, **Rivkees, SA.** Receptor Localization and Labeling Methods and Practice. IN: Immunocytochemical Analysis of Neurotransmitter Receptors. Ed. M. Ariano, Wiley-Liss, 1998. P 91-106.
10. **Rivkees SA**, Sklar C, Freemark M. The Management of Graves' Disease in Children with Special Emphasis on Radioiodine Treatment. J Clinical Endocrinology and Metabolism 83:3767-3776, 1998.
11. **Rivkees SA**, Ijzerman AP, Swanson TS. New Insights into the Molecular Mechanisms of A_1 Adenosine Receptor Action. Drug Development Research 43:93-102, 1998.
12. **Rivkees SA**. The Management of Graves' Disease in Children. IN: Graves disease. Ed. B. Rapaport. 2000: 185-204
13. **Rivkees SA**, Hao H. The development of circadian rhythmicity. Seminars in Perinatology 2000 24(4):232-42.
14. **Rivkees SA.** Thyroid disease in children and adolescents. IN: Contemporary Endocrinology Ed. E. Eugster and O Pescovitz 2001: 145-182.
15. **Rivkees SA**. Mechanisms and Clinical Significance of Circadian Rhythms. Current Opinions in Pediatrics 13:352-357, 2001.
16. **Rivkees SA**. Circadian rhythms and disorders of the circadian system. IN: Recent Advances in Pediatrics Ed: TJ David. Churchill Livingstone. 187-196, 2001.
17. **Rivkees SA**. The use of radioactive iodine in the management of hyperthyroidism in children. Curr Drug Targets Immune Endocr Metabol Disord 2001 1(3):255-64
18. **Rivkees SA**, Turner CP, Zhao Z, Porter GP. Influences of adenosine on the fetus and newborn. Molecular Genetics and Metabolism 74:160-171, 2001
19. **Rivkees SA.** Mechanisms and Clinical Significance of Circadian Rhythms in Children. Current Opinions in Pediatrics Mechanisms and clinical significance of circadian rhythms in children. 2001 13(4):352-7.
20. **Rivkees SA**. Circadian rhythms-genetic regulation and clinical disorders. Growth, Genetics and Hormones 18:1-6, 2002.
21. Rice AR, **Rivkees SA**. Paradigms of hormone action: Signaling pathways and receptors. IN: Pediatric Endocrinology. Ed: M. Sperling 2002: 5-47.
22. **Rivkees SA.** Developing circadian rhythmicity in infants. Pediatrics. 2003 112(2):373-81.

23. **Rivkees SA.** Emergence and influences of circadian rhythmicity in infants. Clin Perinatol. 2004 Jun;31(2):217-28, v-vi.
24. Back SA, **Rivkees SA.** Emerging concepts in periventricular white matter injury. Semin Perinatol. 2004 28(6):405-14.
24. **Rivkees SA.** The Treatment of Graves' Disease in Children. J Pediatr Endocrinol Metab. 2006 19(9):1095-111.
25. **Rivkees SA,** Dinauer C. The Use of 131-Iodine in the Treatment of Graves' Disease in Children. In Comprehensive Handbook on Iodine: Nutritional, Endocrine and Pathological Aspects 2007
26. **Rivkees SA**. The Development of Circadian Rhythms: From Animals To Humans. Sleep Clinics in Medicine 2007
27. **Rivkees SA,** Dunbar N, Wilson TA. The Management of Central Diabetes Insipidus in Infancy: Desmopressin, Low renal solute load formula, Thiazide Diuretics. J Pediatr Endocrinol Metab. 2007 Apr;20(4):459-69.
28. Dinauer CA, Breuer C, **Rivkees SA.** Differentiated thyroid cancer in children: diagnosis and management. Curr Opin Oncol. 2008, 20(1):59-65.
29. **Rivkees SA**. Differentiating appropriate antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion and cerebral salt wasting: the common, uncommon, and misnamed. Curr Opin Pediatr. 2008 20(4):448-52.
30. **Rivkees SA, Mattison D.** Propylthiouracil (PTU)-induced Liver Failure and Recommendations for the Discontinuation of PTU Use in Children. Internat J Pediatr Endocrinol 2009 Article ID 132041, 8 pages, 2009. doi:10.1155/2009/132041.
31. **Rivkees SA.** Dexamethasone Therapy of Congenital Adrenal Hyperplasia and the Myth of the 'Growth Toxic' Glucocorticoid. Internat J Pediatr Endocrinol 2010;2010:569680.
32. **Rivkees SA.** Controversies of radioactive iodine use in children. Hormone Research. 2010;74(5):305-11. Epub 2010 Oct 2.
33. **Rivkees SA,** Wendler CW. Adverse and Protective Influences of Adenosine on the Newborn and Embryo: Implications for Preterm White Matter Injury and Embryo Protection. Pediatric Res. 2011 69(4):271-8.
34. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, **Rivkees SA,** Ross DS, Sosa JA, Stan MN.Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011.
35. Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, Baker LA, Baratz AB, Baskin LS, Berenbaum SA, Breault DT, Cerame BI, Conway GS, Eugster EA, Fracassa S, Gearhart JP, Geffner ME, Harris KB, Hurwitz RS, Katz AL, Kalro BN, Lee PA, Alger Lin G, Loechner KJ, Marshall I, Merke DP, Migeon CJ, Miller WL, Nenadovich TL, Oberfield SE, Pass KA, Poppas DP, Lloyd-Puryear MA, Quigley CA, Riepe FG, Rink RC, **Rivkees SA,** Sandberg DE, Schaeffer TL, Schlussel RN, Schneck FX, Seely EW, Snyder D, Speiser PW, Therrell BL, Vanryzin C, Vogiatzi MG, Wajnrajch MP, White PC, Zuckerman AE. Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol. 2010;2010:275213.
36. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, **Rivkees** SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011 May-Jun;17(3):456-520.
37. **Rivkees** SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev. 2011 Dec;32(6):798-826.

38. **Rivkees** SA, Wendler CC. Regulation of cardiovascular development by adenosine and adenosine-mediated embryo protection. Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):851-5.
39. **Rivkees** SA, Mandel SJ. Thyroid disease in pregnancy. Horm Res Paediatr. 2011;76 Suppl 1:91-6.
40. **Rivkees SA.** Thyroid Disorders in Children and Adolescents. In: Pediatric Endocrinology. Ed. MA Sperling. Esevier. 2014
41. **Rivkees** SA. Pediatric Graves' disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014;2014(1):10. doi: 10.1186/1687-9856-2014-10. Epub 2014.
42. **Rivkees** SA.Controversies in the management of Graves' disease in children. J Endocrinol Invest. 2016 Nov;39(11):1247-1257. Epub 2016 May 6. Review.
43. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, **Rivkees** SA, Samuels M, Sosa JA, Stan MN, Walter MA 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421.
44. **Rivkees SA,** Peter F. Hyperthyroxinemia. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
45. **Rivkees SA,** Peter F. Neonatal hyperthyroidism.In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
46. Peter F, **Rivkees SA**. Congenital hypothyroidism. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
47. Peter F, **Rivkees SA**. Hyperthyroidism. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
48. Peter F, **Rivkees SA**. Juvenile hypothyroidism. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
49. Peter F, **Rivkees SA**. Goiter. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
50. Peter F, **Rivkees SA**. Thyroid nodules in children and adolescents. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
51. Peter F, **Rivkees SA**. Thiroid carcinoma. In Practical Algorithms in Pediatric Endocrinology. Ed. Z. Hochberg. Karger. 2017
52. **Rivkees SA**, Bauer AJ. Thyroid Disorders in Children and Adolescents. Contemp. Peds.
53. **Rivkees SA**, Bauer AJ. Thyroid Disorders in Children and Adolescents. . In: Pediatric Endocrinology. Ed. MA Sperling. Esevier. 2019.
54. **Rivkees SA.** Hyperthyroidism in the Neonate, Child and Adolescent. In: Warner and Ingbars The Thyroid
55. **Rivkees SA.** Hyperthyroidism in the Children and Adolescents. In: Thyroid and Parathyroid Disorders in Children: A Practical Handbook. VitalSource® ebook. 2020

5. Editorials/Commentaries

1. **Rivkees SA**. Time to wake-up to the individual variation in sleep needs. J Clin Endocrinol Metab 2003 88(1):24-5
2. **Rivkees SA**. Radioactive iodine use in childhood Graves' disease: time to wake up and smell the I-131. J Clin Endocrinol Metab. 2004 89(9):4227-8.
3. **Rivkees SA.** Whither the "case report and review of the literature"? Bring on research networks. J Pediatr Endocrinol Metab. 2006 19(7):871-2. No abstract available.
4. **Rivkees SA.** Do we need to build a different "better mousetrap"? J Pediatr Endocrinol Metab. 2006 19(8):961-2.
5. **Rivkees SA.** Beyond the Karyotype: Are New Screening Methods Needed for Girls with Turner Syndrome? "? J Pediatr Endocrinol Metab. 2006 19(10):1187-9.

6. **Rivkees SA.** This is Not Your Mentors NIH - New Strategies for Research Support. J Pediatr Endocrinol Metab. 2006 19(10):1187-9.
7. **Rivkees SA.** When is “it’s sort of a boy and sort of a girl” sort of a boy and sort of a girl? J Pediatr Endocrinol Metab. 2006 19(11):1285-9.
8. **Rivkees SA.** Turning negatives to positives--moving mudslinging to child health betterment. J Pediatr Endocrinol Metab. 2006 19(12):1375-6.
9. **Rivkees SA.** Radioactive iodine: an ideal form of therapy for childhood Graves’ Disease. J Clin Endocrinol Metab. 2007; 92(3):797-800.
10 **Rivkees SA.** Should off-label drug use be off-the-table? J Pediatr Endocrinol Metab. 2007;20(2):171-2.
11. **Rivkees SA.** Continued catch-up growth in neonatal endocrinology. J Pediatr Endocrinol Metab. 2007:20(3), 357-358.
12. **Rivkees SA.** Academic Pediatrics: The looming question. J Pediatrics. 2007;151(3):223-4.
13. **Rivkees SA.** The Newborn Screening Saves Lives Act: 4 million calls for support. J Pediatr Endocrinol Metab. 2007 20(4):457-8.
14. **Rivkees SA.** Advertised Calories per Hour 2000+: Anti-Obesity Announcements per Hour 0. J Pediatr Endocrinol Metab. 2007 20(5):557-8.
15. Rivkees SA. No child need have unrecognized diabetes mellitus. J Pediatr Endocrinol Metab. 2007 20(10):1055-7.
16. **Rivkees SA.** Graves' disease therapy in children: truth and inevitable consequences. J Pediatr Endocrinol Metab. 2007 20(9):953-5.
17. **Rivkees SA.** McCune-Albright syndrome: 70 years of fascination and discovery. J Pediatr Endocrinol Metab. 2007 20(8):849-51.
18. **Rivkees SA.** The early seeds of obesity: Are childhood obesity programs too late to the table. J Pediatr Endocrinol Metab. 2008 21(1):1-2.
19. **Rivkees SA.** Review or de-review. J Pediatr Endocrinol Metab. 2008 21(2).
20. **Rivkees SA,** Mecurio MP. Performance enhancing endocrinology. The arbitrary line of acceptability. J Pediatr Endocrinol Metab. 2008 21(3):197-9
21. **Rivkees SA.** Lost lessons of glucocorticoid potency and the treatment of children with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2008 21(4):297-9.
22. **Rivkees SA.** Why the consensus for consensus? J Pediatr Endocrinol Metab. 2008 21(6):503-5.
23. **Rivkees SA.** The long arm of financial conflicts of interest: extensions into lined pockets, research and review, and the United States Senate. J Pediatr Endocrinol Metab. 2008 ;21(7):607-9.
24. **Rivkees SA.** Medical Moneyball: a model for academic pediatric growth. J Pediatr Endocrinol Metab. 2008 Aug;21(8):713-6
25. **Rivkees SA.** Fat and the beanstalk. J Pediatr Endocrinol Metab. 2008 Sep;21(9):821-2.
26. **Rivkees SA.** “Primum Non Nocere” (First, not to harm) and “Secundus, Opinio Vulnero” (Second, report the harm). Internat J Pediatr Endocrinol 2009.
27. **Rivkees SA.** The Inauguration of a New Term of Pediatric Endocrinology. Internat J Pediatr Endocrinol 2009.
28. Cooper DS, **Rivkees SA.** Putting Propylthiouracil in Perspective. J Clin Endocrinol Metab. 2009 Jun;94(6):1881-2.
29. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein IL, Laurberg P, McDougall R, **Rivkees SA**, Ross D, Sosa, J.A., Stan MN. The Role of Propylthiouracil (PTU) in the Management of Graves’ Disease in Adults: Report of a meeting jointly sponsored by the ATA and the FDA. Thyroid. 2009;19(7):673-4.
30. **Rivkees SA.** 63 years and 715 days to the "boxed warning": unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol. 2010;2010. pii: 658267.

31. **Rivkees SA.** Perspective: Tectonic Shifts in Academic Pediatrics: Changes and Adaptation. Acad Med. 2011
32. **Rivkees** SA. International Journal of Pediatric Endocrinology: Excellence, accessibility, expansion, and evolution. Int J Pediatr Endocrinol. 2011;2011(1):1. doi: 10.1186/1687-9856-2011-1. Epub 2011 Jun 21.
33. **Rivkees** SA. Propylthiouracil versus methimazole during pregnancy: an evolving tale of difficult choices. J Clin Endocrinol Metab. 2013 Nov;98(11):4332-5.
34. **Rivkees SA.** The Missing Link of NIH Funding in Pediatric Research Training Program Restructuring. Pediatrics 2014;134(6):e1521-2.
35. **Rivkees SA.** Evaluating the Rare and Predicting the Worst: Lessons for Thyroid Nodules..J Pediatr. 2015 Aug 11. pii: S0022-3476(15)00815-X. doi: 10.1016/j.jpeds.2015.07.037
36. **Rivkees** SA, Daniels SR When policy, demographics, and disease collide: the penalty of poor diabetes care in immigrant children. Pediatr Res. 2016 Sep;80(3):328-9.
37. Russell K, Oliver SE, Lewis L, Barfield WD, Cragan J, Meaney-Delman D, Staples JE, Fischer M, Peacock G, Oduyebo T, Petersen EE, Zaki S, Moore CA, Rasmussen SA; Contributors..Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection - United States, August 2016. MMWR Morb Mortal Wkly Rep. 2016 Aug 26;65(33):870-878. doi: 10.15585/mmwr.mm6533e2.
38. **Rivkees SA.** Pediatric collateral damage from recreational marijuana use. Pediatr Res. 2017 Mar 22. doi: 10.1038/pr.2017.36.
39. Laventhal N, **Rivkees S**, Opipari V. Hope vs. caution: Ethical and regulatory considerations for neonatal stem cell therapies. Pediatr Res. 2017 Dec 15. doi: 10.1038/pr.2017.320.
40. **Rivkees** SA, Denne S. Influences of medications on the developing fetus: toward deciphering the unknowns. Pediatr Res. 2017 Nov;82(5):723-724.
41. **Rivkees** SA, Opipari V, Denne S; Pediatric Policy Council. Commentary from the pediatric policy council 2018: the year of living dizzyingly. Pediatr Res. 2018 Sep 5.
42. **Rivkees** SA; From the Pediatric Policy Council. Cherishing family values: let us not let immigration policy harm children. Pediatr Res. 2018;84(2):149-150.
43. **Rivkees** SA, Opipari V; Pediatric Policy Council. Ensuring the care for our youngest graduates with medically complex conditions. Pediatr Res. 2018 Nov 19. doi: 10.1038/s41390-018-0233-3.
44. Fleiss B, **Rivkees** SA, Gressens P. Early origins of neuropsychiatric disorders. Pediatr Res. 2019 Jan;85(2):113-114. doi: 10.1038/s41390-018-0225-3

6. Books/Monographs

1. **Rivkees SA,** Editor: Seminars in Perinatology. Development of circadian rhythmicity. Seminars in Perinatology 2000.
2. **Rivkees SA.** Editor: Seminars in Perinatology. Perinatal Brain Injury. Seminars in Perinatology 2004.
3. **Rivkees SA,** Hsu C. Congenital Adrenal Hyperplasia: A guide for parents 2005. AuthorHouse, Bloomington IN.
4. **Rivkees SA,** Standhope R, Touraine P, Trainer. (Editor), Growth Hormone and Growth Factors in Endocrinology and Metabolism. 2005
5. Krassas G, **Rivkees SA,** Kiess A. Diseases of the Thyroid in Children and Adolescents. 2006 Karger Press.
6. Gruter A, Hagenas L, Monson JP, **Rivkees SA**, Popovic-Brkic V. (Editor). 39th International Sumposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism. 2007
7. **Rivkees SA,** Hoffman P. (Editor). 41st International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism. 2009

8. **Rivkees SA.** Resident On Call. A Doctor's Reflections on His First Years at Mass General. Lyons Press (2014)

7. Grant History:

1987-1989 Pediatric Career Scientist Training Program Award
NICHD
Fellowship Award
Direct Costs $48,060/yr; Total Direct Costs $105,000
Principal Investigator
Percent Effort: 100%

1989-1991 Lawson Wilkins Pediatric Endocrine Society/Genentech
Clinical Scholar Award
Direct Costs $35,000/yr; Total Direct Costs $70,000
Principal Investigator
Percent Effort: 40%

1990-1993 NICHD Clinical Investigator Award HD00924
"Neurobiology of Melatonin Action"
Direct Costs $71,635/yr; Total Direct Costs $187,272
Principal Investigator
Percent Effort: 75%

1993-1994 Genentech Clinical Study Award
"Growth Hormone Treatment of Glucocorticoid-Induced Growth Failure"
Direct costs $35,000/yr; Total Direct Costs $70,000
Principal Investigator
Percent Effort: 15%

1990-1995 R01 DK42125
"Melatonin: Sites and Mechanisms of Hormone Action"
Direct Costs $172,000/yr; Total Direct Costs $983,952
Co-Investigator

1992-1998 R01 HD14427-11
"Maternal Influence on Developing 24-Hour Periodicity"
Direct Costs $187,185/yr; Total Direct Costs $987,669
Co-Investigator

1993-1995 Riley Memorial Association Award
"Development of a Primate Clock"
Direct costs $37,000/yr; Total Direct Costs $74,000.
Principal Investigator
Percent Effort: 25%

1995-1996 Human Growth Foundation/Fellowship Support Award
"Adenosine Influence on Somatotroph Function"
Direct/Total Costs $48,000/yr
Principal Investigator
Percent Effort: 15%

1993-1996 American Heart Association, Grant-in Aid
"Localization of Adenosine Receptors in Human Heart"
Direct costs $44,000/yr; Total Direct Costs $120,000
Principal Investigator
Percent Effort: 25%

1993-1995 Genentech Clinical Study Award
"Growth Hormone Treatment of Glucocorticoid-Induced Growth Failure"
Direct costs $35,000/yr; Total Direct Costs $70,000

Principal Investigator
Percent Effort: 20%

1994-1998 NINDS 1RO1NS32624-01
"Developing Circadian Rhythmicity in a Primate"
Direct costs $197,917/yr; Total Direct Costs $1,059,418
Principal Investigator
Percent Effort: 25%

1996-1999 NINDS RO1 NS33539-01
"Human A1-Adenosine Receptor Action in Human Hippocampus"
Direct Costs $173,677/yr; Total Direct Costs $737,511
Principal Investigator
Percent Effort: 25%

1997-2001 NHLBI RO1HL58442
“Influence of Adenosine on the Developing Heart”
Direct Costs $180,677/yr; Total Direct Costs $880,000
Principal Investigator
Percent Effort: 25%

1999-2001 Human Growth Foundation
“Biological Clock Function in Children with Neuroendocrine Dysfunction”.
Direct Costs $50,000/yr; Total Direct Costs $100,000
Principal Investigator
Percent Effort: 15%

1999-2004 NINDS 1RO1NS32624-06
"Developing Circadian Rhythmicity in a Primate"
Direct costs $208,917/yr; Total Direct Costs $1,230,108
Principal Investigator
Percent Effort: 25%

1999-2004 Donaghue Medical Research Foundation
“Prevention of Brain Injury in Premature Infants”
Direct Costs $110,677/yr; Total Direct Costs $600,000
Principal Investigator
Percent Effort: 25%

1999-2004 Fanny Ripple Foundation
“YCHRC Imaging Center”
Direct Costs $140,000/yr; Total Direct Costs $240,000
Co-Investigator
Percent Effort: 5%

2000-2005 NINDS RO1 NS33539-06
"Human A1-Adenosine Receptor Action in Human Hippocampus"
Direct Costs $200,000/yr; Total Direct Costs $800,000
Principal Investigator
Percent Effort: 25%

2000-2005 American Cancer Society
“Determination of Molecular Binding Site in Human A1 Adenosine Receptor”
Direct costs $50,000/yr; Total Direct Costs $200,000
Co- Investigator
Percent Effort: 10%

2000-2002 NIH: Diabetes Research Center Pilot Project
“Hypoglycemic Brain Injury During Development”
Principal Investigator
Direct costs $25,000/yr; Total Direct Costs $50,000
Co- Investigator

Percent Effort: 10%

2001-2006 NHLBI RO1HL58442
"Influence of Adenosine on the Developing Heart"
Principal Investigator
Direct costs $200,000/yr; Total Direct Costs $800,000
Co- Investigator
Percent Effort: 20%

2003-2006 NIH NS045310-01
"Purinergic Mechanisms of Hypoglycemic Brain Injury"
Principal Investigator
Direct costs $125,000/yr; Total Direct Costs $250,000
Co- Investigator
Percent Effort: 10%

2003-2004 NIH STTR
"Vaccine Therapy of Congenital Adrenal Hyperplasia"
Principal Investigator
Direct costs $125,000/yr; Total Direct Costs $125,000
Co- Investigator
Percent Effort: 10%

2004-2007 United Cerebral Palsy Foundation
"Prevention of Periventricular Leukomalacia"
Principal Investigator
Direct costs $50,000/yr; Total Direct Costs $100,000
Percent Effort: 10%

2004-2005 NIH STTR
"Development of ACTH antagonist"
Principal Investigator
Direct costs $125,000/yr; Total Direct Costs $125,000
Co- Investigator
Percent Effort: 10%

2005-2008 NIH 1R21DA019344-01
Principal Investigator
Direct costs $175,000/yr; Total Direct Costs $250,000
"CB1 Receptor Action on the Developing Hippocampus"
Percent Effort: 20%

2000-2005 NIH K12 01401-05
"Developmental Adaptation: Child Health Research Center"
Program Director
Direct costs $380,000/yr; Total Direct Costs $1,900,000
Percent Effort: 10%

2004-2008 Juvenile Diabetes Research Foundation
"Mechanisms of Hypoglycemia-Induced White Matter Injury"
Direct costs $160,000/yr; Total Direct Costs $500,000
Percent Effort: 20%

2006-2009 March of Dimes
"Prenatal Adenosine action"
Principal Investigator
Direct costs $150,000/yr

2005-2006 NIH R41 HD049230
"Newborn Screening for Sex Chromosome Disorders"
Principal Investigator
Direct costs $150,000/yr; Total Direct Costs $150,000

2006-2009 R21NS051191-01A1
"Anti-Adenosine Therapy of Brain Injury"
Principal Investigator
Direct costs $175,000/ yr; Total Direct Costs $275,000

2006-2009 R21NS051191-01A1
"Anti-Adenosine Therapy of Brain Injury"
Principal Investigator
Direct costs $175,000/ yr; Total Direct Costs $275,000

2006-2009 5R42DK068913-03
"Development of ACTH antagonists"
Co-Principal Investigator
Direct costs $450,000/ yr; Total Direct Costs $750,000

2008-2010 1R43HD058387-01 (JS Genetics)
“Development of Novel Diagnostics for Fragile X Syndrome”
Direct costs $156,000/ yr; Total Direct Costs $156,000

2008-2010 1R43NS060188-01A1 (JS Genetics)
Co-Principal Investigator
“Identification of Oligodendrocyte Stimulators”
Direct costs $150,000/ yr; Total Direct Costs $150,000

2006-2011 2K12HD001401-06
"Developmental Adaptation- Child Health Research Center"
Program Director
Direct costs $400,000/ yr; Total Direct Costs $2,000,000

2006-2011 NICHD
"Training Program in Perinatology"
Co-Director
Direct costs $150,000/ yr; Total Direct Costs $600,000

2007-2010 2R42HD049230-02
“Newborn Screening for Sex Chromosome Disorders”
Co-Principal Investigator
Direct costs $450,000/ yr; Total Direct Costs $750,000

2008-2010 United Cerebral Palsy Foundation
“Novel Therapeutics for White Matter Injury”
Principal Investigator
Direct costs $75,000/ yr; Total Direct Costs $150,000

2010-2012 2R44NS060188-02A1 (JS Genetics)
Co-Principal Investigator
“Identification of Oligodendrocyte Stimulators”
Direct costs $475,000/ yr; Total Direct Costs $975,000

2010-2012 2R44HD058387-02 (JS Genetics)
Investigator
“Development of Novel Diagnostics for Fragile X Syndrome”
Direct costs $485,000/ yr; Total Direct Costs $995,000

2010-2015 2K12HD00140
Yale Child Health Research Center Development Program
Program Director
Direct costs $400,000/yr; Total Direct Costs $2,000,000

2011-2016 NICHD
Training Program in Perinatology
Co-Director
Direct costs $150,000/ yr; Total Direct Costs $600,000

2011-2016 1T32HD068201-01

NICHD
Yale Pediatrics Basic Science Training Program
Principal Investigator
Direct costs $390,000/yr; Total Direct Costs $1,890,222

2009-2016 1R01HD056281-0A1
“Adenosine-Mediated Fetal Growth Retardation”
Principal Investigator
Direct costs $250,000/ yr; Total Direct Costs $500,000

2008-2015 Thrasher Foundation
“Identification of Biological Clock Dysfunction in Optic Nerve Hypoplasia”
Principal Investigator
Direct costs $100,000/ yr; Total Direct Costs $300,000

2010-2015 1R01HD065200-01
Principal Investigator
“Graves' Disease Therapy Risks to Mother and Fetus”
Principal Investigator
Direct costs $500,000/ yr; Total Direct Costs $1,900,000

2010-2015 1R01NS068039-01
“Periventricular White Matter Prevention”
Principal Investigator
Direct costs $250,000/ yr; Total Direct Costs $1,250,000

2013-2015 Principal Investigator
“Children’s Medical Services Integrated Care Program”
Florida Dept. of Health
Total Direct Costs $52,855,942.32

2012-2016 Principal Investigator
“Children’s Medical Services”
Florida Dept. of Health
Direct Costs $960,000/yr

2012-2017 1 R01 FD003707-01
Principal Investigator
“Radioactive Iodide Therapy of Pediatric Graves' Disease”
Principal Investigator
Direct costs $280,000/ yr; Total Direct Costs $1,600,000

2016-2018 R41 NS095475-01
Principal Investigator
“Discovery of Oligodendrocyte Stimulators”
Total Direct Costs: $258,192

2016-2018 5R21NS091866-02
Investigator
“Cortical Circuit Formation and Plasticity Following Neonatal Brain Injury”
Total Costs: $275,000

2012-2019 Principal Investigator
“Title XIX Program”
Florida Dept. of/yr

2013-2019 Principal Investigator
“Children’s Medical Services”
Florida Dept. of Health
Total Direct Costs $18,068,821.34/yr

2019-2022 1 R42 HD097911-01A1
Principal Investigator
‘Prevention of White Matter Injury in Premature Infants”

Direct Costs: $1,725,000.00

2019- 2021 1 R41 DK123953-01
Principal Investigator
Development of a novel therapeutic for hyperthyroidism
Direct Costs: $200.000

Updated 09/10/2021